February 17, 2017
As many of you know, the 21st Century Cures Act, which was signed into law in December 2016, authorizes $1.8 billion over 7 years to fund the Beau Biden Cancer MoonshotSM. This additional funding, $300 million of which is available in Fiscal Year 2017, enables NCI to accelerate research efforts aligned with the Cancer Moonshot and build upon the progress that has been achieved over the years. I am pleased to update you on NCI’s activities to begin implementing these initiatives.
Even before the Cures Act was passed, we took the preliminary step of identifying funding opportunity announcements (FOAs) from within NCI’s extensive funding portfolio that aligned with the goals of the Moonshot, and posted these FOAs to NCI’s Cancer Moonshot webpage, to simplify the process of searching for funding opportunities that support Cancer Moonshot-related research. Today, we have updated that list with additional opportunities to mark the beginning of a growing Cancer Moonshot portfolio.
Planning for implementation of longer-term scientific initiatives is also underway. We have established implementation teams aligned with the BRP recommendations. The teams include NCI extramural and intramural scientists, and experts from several other NIH institutes and centers. Team members are considering multiple ways to fund the best science, including grants, supplements, and other mechanisms, and, where appropriate, to form partnerships with foundations, academia, and the private sector. We look forward to engaging our extramural colleagues in this process.
I am very optimistic that the support provided by the Cures Act and working together with all of you will enhance our ability to make great strides in transforming the future of cancer research and patient care.
Douglas R. Lowy, M.D.
National Cancer Institute